Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study

ABSTRACT Background: Reducing low-density lipoprotein cholesterol (LDL-C) levels to National Cholesterol Expert Panel (NCEP) goal is recommended. However, sex-specific effects may influence benefit. Methods and results: In this post hoc analysis of the GREek Atorvastatin and Coronary heart disease (...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2008-06, Vol.24 (6), p.1593-1599
Main Authors: Athyros, Vasilios G., Kakafika, Anna I., Papageorgiou, Athanasios A., Paraskevas, Kosmas I., Tziomalos, Konstantinos, Anagnostis, Panagiotis, Pagourelias, Efstathios, Koumaras, Charalambos, Karagiannis, Asterios, Mikhailidis, Dimitri P.
Format: Article
Language:English
Subjects:
Adult
Aged
Anticholesteremic Agents - administration & dosage
Anticholesteremic Agents - pharmacology
Anticholesteremic Agents - therapeutic use
Atorvastatin Calcium
Cardiovascular events
Cholesterol, LDL - drug effects
Coronary Disease
Female
Follow-Up Studies
Glomerular filtration rate
Heptanoic Acids - administration & dosage
Heptanoic Acids - pharmacology
Heptanoic Acids - therapeutic use
High density lipoprotein
Humans
Hypercholesterolemia - drug therapy
Male
Men
Middle Aged
Outcome Assessment (Health Care)
Pyrroles - administration & dosage
Pyrroles - pharmacology
Pyrroles - therapeutic use
Renal function
Sex Factors
StatinsWomen
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Background: Reducing low-density lipoprotein cholesterol (LDL-C) levels to National Cholesterol Expert Panel (NCEP) goal is recommended. However, sex-specific effects may influence benefit. Methods and results: In this post hoc analysis of the GREek Atorvastatin and Coronary heart disease (CHD) Evaluation [GREACE] study we investigated the extent in vascular event reduction by statin treatment according to sex. From a total of 1600 patients with stable CHD, 624/176 and 632/168 were men/women on atorvastatin or on usual care, respectively. During 3-year follow-up, comparison of atorvastatin treatment with usual care demonstrated a relative risk reduction (RRR) of the primary end point (all vascular events) of 54 % in women (hazard ratio [HR] 0.46, 95 % confidence interval [CI] 0.24–0.87, p = 0.003) and of 50 % in men (HR 0.50, 95 % CI 0.32–0.70, p 
ISSN:0300-7995
1473-4877
DOI:10.1185/03007990802069563